52
Participants
Start Date
October 31, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
June 30, 2015
Regorafenib, ophthalmic oily suspension (BAY73-4506)
Subjects receive Regorafenib as eye drops
Sham IVT
Sham injections
Ranibizumab
Subjects receive Ranibizumab as intravitreal injection
Placebo
Placebo eye drops
Bogotá
Lausanne
Budapest
Vienna
Budapest
Vienna
Budapest
Sydney
Strathfield
Westmead
Parramatta
Bern
Debrecen
Nedlands
Pécs
Zurich
Berlin
West Mifflin
Milan
Milan
Milan
Hamburg
Charlottesville
Asheville
Greenville
Decatur
Boredaux
Udine
Miami
Plantation
Boynton Beach
Winter Haven
Fort Myers
Sarasota
Stuart
Padua
Bologna
Louisville
Seville
Seville
Valencia
Valencia
Valladolid
New Albany
Münster
Barakaldo
Busan
Grand Rapids
Florence
Cologne
Bonn
Mainz
Rapid City
Ancona
Florissant
Leawood
Wichita
Lyon
Eunice
Tübingen
Paris
Temple
Houston
The Woodlands
San Antonio
McAllen
Austin
Golden
München
München
Bratislava
Tucson
Beverly Hills
Arcadia
Trenčín
Costa Mesa
Laguna Hills
Santa Ana
Mountain View
Campbell
Afula
Haifa
Haifa
Kfar Saba
Petah Tikva
Ramat Gan
Osorno
Ẕerifin
Tel Aviv
Metropolitana
Rehovot
Vitacura
Santiago
Beersheba
Jerusalem
Boston
Teaneck
Calgary
Edmonton
Vancouver
Halifax
London
Mississauga
Montreal
Montreal
Sherbrooke
Hradec Králové
Prague
Prague
Prague
Dresden
Dresden
Leipzig
Hong Kong
Kowloon
Rome
Rome
Sassari
Inba-gun
Fukuoka
Miyako-gun
Sapporo
Sapporo
Himeji
Yamato
Yokohama
Kumamoto
Iga
Nagasaki
Nara
Osaka
Osaka
Chōfu
Itabashi-ku
Ōta-ku
Taito-ku
Ružomberok
Žilina
Žilina
Seongnam-si
Incheon
Seoul
Seoul
Seoul
Seoul
Albacete
Barcelona
L'Hospitalet de Llobregat
San Cugat Del Vallès
Lead Sponsor
Bayer
INDUSTRY